NNRTI (HIV)
Rilpivirine
Brand names: Edurant
Adult dose
Dose: 25mg PO OD with food
Route: PO
Frequency: OD
Clinical pearls
- HIV-1 in treatment-naive with VL ≤100,000 and CD4 >200
- Take with full meal (300+ kcal); long-acting cabotegravir+rilpivirine for maintenance
Contraindications
- Concurrent strong CYP3A4 inducers
- PPIs (avoid)
- HIV viral load >100,000 copies/mL at initiation
Side effects
- Insomnia
- Headache
- Depression
- Hepatotoxicity
- QT prolongation
- Severe skin reactions
Interactions
- PPIs (avoid)
- H2 blockers (separate by 12h)
- Antacids
- Strong CYP3A4 modulators
Monitoring
- HIV VL/CD4
- LFTs
Reference: BNF; BHIVA; https://bnf.nice.org.uk/drugs/rilpivirine/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023